## Background: Although experimental studies have demonstrated an important role of insulin-like growth factor i (igf-i) in hepatocarcinogenesis, the clinical data about igf-i in patients with hepatocellular carcinoma (hcc) are scarce and controversial. to the authors' knowledge, this is the first
Phenotype 2 of deoxyribonuclease I may be Used as a risk factor for gastric carcinoma
β Scribed by Souichi Tsutsumi; Takayuki Asao; Yukio Nagamachi; Tamiko Nakajima; Toshihiro Yasuda; Koichiro Kishi
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 76 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
Human deoxyribonuclease i (dnase i) (ec3.1.21.1) is one of the candidate nucleases that acts in mammalian cells during apoptosis. genetic polymorphism of dnase i has been classified into 15 phenotypes controlled by 5 autosomal codominant alleles. the purpose of this study was to determine whether dnase i polymorphism is closely related to the incidence of gastric carcinoma.
Methods:
The phenotype distribution was examined using urine samples obtained from unrelated japanese patients with gastric carcinoma (n = 97) and benign gastric diseases (n = 76). phenotyping was performed using isoelectric focusing electrophoresis in thin polyacrylamide gel and immunoblotting with an antihuman dnase i antibody.
Results:
A close statistical association was found between patients with gastric carcinoma and a high frequency of dnase i phenotype 2. however, there was no significant difference in the phenotype distribution between the group of patients with benign gastric diseases and the controls.
Conclusions:
The findings of the current study suggest that dnase i phenotype 2 may be a marker for gastric carcinoma. therefore, compared with other phenotypes, dnase i phenotype 2 may have potential for identifying patients who are at risk of harboring or developing gastric carcinoma.
π SIMILAR VOLUMES